Search Results - "Baroldi, P."

Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR®) in adults with partial-onset seizures by Chung, S. S., Johnson, J. K., Brittain, S. T., Baroldi, P.

“…Objective To evaluate long‐term outcomes of adjunctive therapy with SPN‐804 (Oxtellar XR®, Supernus Pharmaceuticals), an extended‐release tablet formulation of…”
Get full text

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir by KEMPF, D. J, MARSH, K. C, SUN, E, PIZZUTI, D, PLATTNER, J. J, NORBECK, D. W, LEONARD, J. M, KUMAR, G, RODRIGUES, A. D, DENISSEN, J. F, MCDONALD, E, KUKULKA, M. J, HSU, A, GRANNEMAN, G. R, BAROLDI, P. A

“…Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon…”
Get full text

Evaluation of personality as a component of the healthy condition of volunteers participating in phase I studies by BERTO, D, MILLERI, S, SQUASSANTE, L, BAROLDI, P. A

“…The present study was conceived in order to recommend use of the Minnesota Multiphasic Personality Inventory for the evaluation of the personality of…”
Get full text

Efficacy and Tolerability of SPN-804, a Novel, Once-Daily Extended-Release Formulation of Oxcarbazepine as Adjunctive Therapy in Patients with Refractory Partial Seizures (P06.101) by Baroldi, P., Brittain, S., Louro, D., Johnson, J.

“…Abstract only…”
Get full text

Oxcarbazepine Extended-Release (SPN-804) Therapy in Patients with Refractory Partial Seizures: Review of Neurologic and Ophthalmologic Adverse Events (P06.107) by Johnson, J., Brittain, S., Keeler, E., Louro, D., Baroldi, P.

“…Abstract only…”
Get full text

Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial by French, J.A., Baroldi, P., Brittain, S.T., Johnson, J.K.

“…Objective To evaluate the efficacy, tolerability, and safety of once‐daily 1200 mg and 2400 mg SPN‐804 (Oxtellar XR™, Supernus Pharmaceuticals), an…”
Get full text

Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract by Barbanti, G, Maggi, C A, Beneforti, P, Baroldi, P, Turini, D

“…We have extended our earlier observations on pain relief produced by intravesical instillation of capsaicin (10 microM in saline) in patients with…”
Get more information

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients by Mattei, A M, Ferrari, C, Baroldi, P, Cavioni, V, Paracchi, A, Galparoli, C, Romano, C, Spellecchia, D, Gerevini, G, Crosignani, P G

“…To further evaluate the potency and time course of the PRL-lowering effect of single oral doses of cabergoline, two doses of the drug were given to 51…”
Get more information

Venous blood platelets decrease during allergen-induced asthmatic reactions by Maestrelli, P, Boschetto, P, Zocca, E, Crescioli, S, Baroldi, P, Mapp, C, Fabbri, L M

“…To determine whether circulating platelets alter during asthmatic reactions induced by allergens, we studied nine subjects previously shown to develop an early…”
Get more information

A study of plasma disposition kinetics of lacidipine after single oral ascending doses by Squassante, L, Caveggion, E, Braggio, S, Pellegatti, M, Baroldi, P

“…This study was designed to assess the plasma disposition kinetics of single oral 4-, 6-, and 8-mg doses of lacidipine, a new once-daily calcium-entry blocker…”
Get more information

Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug by Pontiroli, A E, Cammelli, L, Baroldi, P, Pozza, G

“…The aim of this study was to evaluate the effectiveness of the ergoline derivative cabergoline in inhibiting the serum PRL response to metoclopramide (MCP; 5…”
Get more information

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir by Hsu, Ann, Granneman, G. Richard, Cao, Guoliang, Carothers, Lori, El‐Shourbagy, Tawalkol, Baroldi, Paolo, Erdman, Keith, Brown, Fran, Sun, Eugene, Leonard, John M.

“…Objective To assess the pharmacokinetic interaction between ritonavir and saquinavir. Methods Ritonavir and saquinavir were administered in single doses to six…”
Get full text

Octylonium bromide interacts competitively with the PAF receptor by Barone, D, Maggi, C A, Baroldi, P, Giachetti, A, Meli, A

“…To clarify the nature of the interaction of octylonium bromide with the PAF receptor, saturation studies of 3H-PAF binding were made in the presence of…”
Get more information

Autoradiographic localization of octylonium bromide binding sites in the rat gastrointestinal tract by Amenta, F, Baroldi, P, Ferrante, F, Napoleone, P, Meli, A

“…The anatomical localization of the binding sites of the spasmolytic drug octylonium bromide (OB) in the rat gastrointestinal tract was analyzed by use of light…”
Get more information

Immunoblockade by a specific tachykinin antiserum of the non-cholinergic contractile responses in the guinea-pig isolated bronchus by Maggi, C A, Patacchini, R, Baroldi, P, Theodorsson, E, Meli, A

“…1. In the guinea-pig isolated bronchus, capsaicin produced a concentration-dependent contraction which was tetrodotoxin- (1 microM) resistant but abolished by…”
Get more information

Effects of Oral and Intravenous Terazosin and Head-up Tilt on Blood Pressure Responses in Patients with Hypertension by Achari, Ramanuj, Hosmane, Balakrishna, Linnen, Paul, Cavanaugh, John, Baroldi, Paolo, Cohen, Albert

“…Terazosin is a selective α1‐adrenoceptor antagonist. A double‐blind, randomized, placebo‐controlled, two‐period study evaluated the effects of posture and of…”
Get full text

Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women by Melis, G B, Gambacciani, M, Paoletti, A M, Beneventi, F, Mais, V, Baroldi, P, Fioretti, P

“…Two different single doses (400 and 600 micrograms) of the new long-acting dopamine agonist cabergoline (CBG) were given to 12 normal cycling women, 17…”
Get more information